Imamura Hiroshi, Furukawa Hiroshi, Kishimoto Tomono, Miyazaki Yasuhiro, Ohshiro Ryouta, Ohta Katsuya, Nakata Yasuyuki, Kamigaki Shunji, Fujimi Satoshi, Takemoto Hiroyoshi, Nakayama Takahiro, Fukunaga Mutsumi, Ohsato Hiroki, Tatsuta Masayuki
Dept. of Surgery, Sakai Municipal Hospital.
Gan To Kagaku Ryoho. 2007 Nov;34(12):2114-6.
A 78-year-old female underwent a curative total gastrectomy with D2 lymphandectomy for advanced gastric cancer in March 2003. S-1 mono-therapy (80 mg/m2, day 1-28/42 days) began as the first-line chemotherapy from October 2004 when multiple lung metastases were detected by CT. Paclitaxel mono-therapy (80 mg/m2, days 1, 8, 15/28 days) began as the second-line chemotherapy from April 2005 when prior S-1 mono-therapy judged as progressive disease (PD) by CT. Paclitaxel mono-therapy judged it as partial response (PR) in June, but the final judgement was as PD in September 2005. S-1 + CPT-11 combination therapy (S-1: 80 mg/m2, day 1-21, CPT-11: 80 mg/m2, days 1, 15/35 days) began as the third-line chemotherapy from September 2005. After 10 courses, multiple lung metastases were judged as complete response (CR) in September 2006. During the third-line chemotherapy, any adverse event of grade 2 or more did not occur. After judgment of CR, the patient has been followed without chemotherapy due to patient's desire, and is still alive without any recurrence in July 2007.